Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree. When people read the email sent to shareholders yesterday and the latest a few news releases are indicating the direction of the company which is very positive.
Approval of this patent by FDA with japanese approval is the game changer and I believe Canada, Europe and China will approve the same patent soon this will make drug manufacturers(big Pharma) lined up to sign up a deal.
People who are affected by these disease need this drug and FDA knew that.
We are not even talking about other developments at the company.
Shares outstanding: 19.51m
Insiders own 22%
There was almost none insider purchase previously.
I believe Christopher Moreau owned only .0049% in the last a few years.
Now, 3.9%?
An other positive big news was a few weeks ago.
———-
“VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, to acquire Algernon’s NP-120 (“Ifenprodil”) research program for USD $2M cash and a 20% common share equity position in Seyltx. The transaction is subject to certain conditions including, inter alia, Seyltx financing and the negotiation and execution of a definitive agreement, which is expected to occur within the next 90 days.
Seyltx plans to conduct an Ifenprodil Phase 2b chronic cough study as soon as possible. As stated in the LOI, Algernon’s clinical management team will be available to provide support, oversight and management of the study.
Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate signaling. Ifenprodil is Algernon’s lead research program and represents a novel first-in-class potential treatment for chronic cough. It is thought to interfere with central signalling in the brain, suppressing the urge to cough.
“We are very pleased to have signed this LOI with Seyltx,” said Christopher J. Moreau, Algernon’s Chief Executive Officer. “With the U.S. FDA advisory panel recently voting 12 – 1 against approving Merck’s chronic cough drug candidate gefapixant, citing a lack of efficacy, it is very important to continue moving Ifenprodil forward as a potential global treatment of chronic cough.”
—————
—————-
Yes, I purchased today at the offer after seeing insider buys.
I could not wait for better deal because with only 19.51 million shares outstanding and insider participation at the same time some loyal share holders are holding. This can be very interesting when and if anything further develops.
========
Note: this is not a recommendation to buy hold or sell the stock, do your own DD.
I think this is going to be a true Blessing for many
It cost me quite more $$ today by not seen your post on 12/28/29, lol.
Agreed, big time.
Moreau stepped up
This is first time I have seen since for a while
Christopher Moreau is the second largest shareholder if the information is accurate.
Beside an excellent news for getting this important patent.
Insider have bought shares in December 2023. Confidence is building.
———
Recent Insider Transactions
========
BuyCA$4,50028 Dec 23
Christopher Moreau
Entity Individual
Role
Chief Executive Officer
CEO & Director
Shares 60,000
Max Price CA$0.075
BuyCA$4,65027 Dec 23
Christopher Moreau
Entity Individual
Role
Chief Executive Officer
CEO & Director
Shares 60,000
Max Price CA$0.077
BuyCA$40,00526 Dec 23
Christopher Moreau
Entity Individual
Role
Chief Executive Officer
CEO & Director
Shares 533,400
Max Price CA$0.075
BuyCA$21,00026 Dec 23
James Kinley
Entity Individual
Role
Chief Financial Officer
Chief Financial Officer
Shares 280,000
Max Price CA$0.075
————
—————
Top Shareholders:
Top 8 shareholders own 22.07% of the company
AlphaNorth Asset Management
15.39%
Christopher Moreau
3.9%
James Kinley
1.49%
Rajpaul Attariwala
0.59%
Harold J. Bloomfield
0.25%
Eldee Foundation, Endowment Arm
0.25%
Howard Gutman
0.11%
Mark Williams
0.093%
=======+=====+
Please make sure you understand. I am not recommending to buy the stock, hold or sell, you do on your own risk do your own DD’s know your risk tolerance, since this is very speculative stock.
Above information may not to be accurate I cannot guarantee for the accuracy, therefore do your own proper o DD’s.
Algernon Pharmaceuticals Gets First US Patent for Repurposed Drug
https://www.streetwisereports.com/article/2023/01/02/pharma-co-gets-first-us-patent-for-repurposed-drug.html?m_t=2024_01_02_09_59_28
Algernon Pharmaceuticals Announces Closing of Private Placement
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-Private-Placement?id=425805
Congrats to Moreau et al!!
Nice to see insider participation
Algernon Pharmaceuticals Announces Increase to Private Placement
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Increase-to-Private-Placement?id=425758
16.8M os? 18.8M os = $400k if?
Hope it's for closing the IPF/CC $2M deal.
Psyc / stroke news please.?.
...GLTA,,,
Outstanding: 15,775,757 posted for December 4, 2023
https://webfiles.thecse.com/11._Algernon_-_CSE_Form_7_-_November_2023.pdf?OXTmTuwbYUf1MVlZ4uJtwQdn_q0KA_Xn
Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-NASH-a?id=423123
Seems to be lots of talk about PTSD - TBI - in the Veteran communities from well respected folks for the use of shrooms and/or CBD. I think this could encompass the stroke recovery research use of psylocibin that our company is trying to move forward and of course a new/large group of patients in need.
It's not over and this latest possible deal may help finance more AGN work. I hope they are talking to some of the Veteran groups that are interested and active in this...
...GLTA...
This is exactly what I was talking about.
“Only thing I can find one page as web page which explains todays news, lol.
It seems it is a new web page set up for this news”.
Just my opinion.
https://seyltx.com/about/ that’s it! Lol again…
Yes,
Seyltx is a U.S.-based Delaware C-corporation
News release gave city in USA
Interesting to search…
No contact info about Seyltx from news release from Algernon today and no web page as well.
One would think anybody spend $2 mil with with 20, would have contact info.
Googled Seyltx.
Only thing I can find one page as web page which explains todays news, lol.
It seems it is a new web page set up for this news.
Is it possible? Of course, I can be wrong here.
Is there a way to find out anything about Seyltx,
who owns it?
Where is located?
Established year?
Contact names(real)?
Propanc has a Caesar share that votes the only vote that counts
Don’t know how it’s legal but I guess if you tell people your screwing rhem before it’s ok
I am not familiar with those cos & news.
How the scam took place, by whom, parties?
Can you enlighten us with more details?
Or their news and posts?
I will appreciate your input. It is good to know.
I have seen this before with po
Ppcb.. but that IS a scam with a Caesar share..
Under capitalized BioPharm is what it is
I hope you are right and I am wrong.
However, I have different opinion about C.Moreau.
——
Here is his leadership team.
Look into R/S history, since he has been running the company.
How many times R/S took place?
Look into company’s capitalization. Has he reduced his remuneration while shareholders were bleeding & burning?
——-
No wonder, they have only consultants.
Can they afford other employees with those salaries?
——-
Leadership Team
Christopher Moreau
CEO & Director
CA$576.45k
James Kinley
Chief Financial Officer
CA$170.04k
Christopher Bryan
Vice President of Research & Operations
CA$257.54k
Note:
Accuracy of this team members and salaries cannot be verified. Please do your own proper DD‘s and know your risk tolerance.
Just my opinion I am not recommending. buy, sell or hold.
It is just my opinion. Good luck to all.
Understood Max
The small base of current shareholders
are NOT going to fund it’s future.
Chris is going to need a new Management team that attracts Capital..
But he bought himself time with this sale..
And Time is a precious thing..
Don’t think overhead quarterly burn very high with no Clinicals in process..
Our Neuro holding doesn’t have expense attached nor our new proposed holding..
Someone posted that all staff are now consultants..
I simply don’t know enough about reprinast..
I would turn to Neuro advantage..
Let’s find a way to make money with Neuro success..either by marketing support or equipment supply..
Let’s look at ambulatory care for stroke victims .. what will Neuro need for rapid test to determine stroke type?
What will Neuro need for immediate dosing?
It’s OUR subsidiary! Let’s use it
$ 2 mil in the bank?
How much are they burning cash a month?
How about overhead payments, research development, etc.
Any other loans to pay ?
Obvious that they could not raise cash any longer from depleted shareholders ?
burn too many times with this stock ?
do your own DD it’s just my opinion .
I also want to say..
Although this may not bring the market cap of agnpf up.. it certainly is a good start to a new trusting process
So 15,000,000 shares at 5 cents puts us at
750,000
With $2,000,000 in bank and 20% equity in ? I have no idea how big private drug co is.. but imagine they would go public or sell with ilfenprodil approval..
we would get 20% of a lot..
ilfenprodil works..I can testify
Maybe Chria can figure out a way
For algernon to partner with algernon Neuro..maybe we can have the marketing rights to DMT for North America..?
Maybe algernon can buy an emergency supplier of Mobile IV kit that algernon Neuro uses..
Now we have cash let’s create a cash flow
Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-LOI-for-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-for-?id=422342
9. Report on any employee hiring’s, terminations or lay-offs with details of anticipated length of lay-offs.
As part of the Company’s efforts to conserve capital, the Company terminated its employment agreements with its employees, however the company continues to operate with its personnel under consulting agreements beginning as of October 1, 2023.
Outstanding: 15,775,757 posted for October 6, 2023
Monthly 5th Report
https://webfiles.thecse.com/9._Algernon_-_CSE_Form_7_-_September_2023.pdf?_2Td4NbezBWyKX3PFrcNh8_oS1KYN5WP
I think Moreau is an honorable man
I don’t think anyone trying to swindle the DMT asset from out underneath agnpf
The problem is .. I don’t think management owns very much stock..
There are no golden handcuffs so to speak.
We should change that either by option or Chria could change that by purchase or both..
AGN needs to publish the CHDR DMT peer review, or/and,
AGN needs to sell their IPF/CC trial results and Ifenprodil rights,
these should get the phase 2 of the Microdose DMT / stroke trial started which is the real possible success story here.
All investors in this speculative stock would be real happy for some good overdue news. Many would then show support with some further investments
...IMHFO...
...GLTA...
Management’s not encouraging anyone to buy their stock … what does that tell you…
Prove me wrong ..
I want to buy more and apologize
So our $15,000,000 asset is valued
at $1.5 million..
Something isn’t right
If I had to guess..
algernon neuroscience is going to buy out its 60-% ownerahip from algernon for a pittance..
Or maybe algernon will go bankrupt and someone will get “lucky” buying the 60% of algernon neuroscience.
This valuation makes zero sense
Zero
Very frustrating
I would buy the heck out of this
if management were doing the same
I just font understand.. insiders have to know the mi no I’m I’m value for this asset:
60% algernon Neuro
Repurpose Patent
Repurpose cough
No money
Is north of $15m
It just smells awful down here at $.10
Like somebody knows something I don’t
The patent is worth $10 m by itself..
does anybody trust Moreau?
Outstanding: 15,775,757 posted for September 8, 2023
Monthly 5th Report
https://webfiles.thecse.com/8._Algernon_-_CSE_Form_7_-_August_2023.pdf?pZ8C.CRdKLA.5xm56A9TAhWNIMThwzv8
I did not exercise, sold the warrants.
I was following the company very closely as a shareholder and I was very positive about the outlook of Algernon.
C. J. Moreau burned to many times shareholders. I have lost complete trust in him. I am sure I am not the only one
He played too many games with shareholder, such as how he advertised and we got sucked in, I know it and I have the copes of his PRs.
Don’t ask about issued warrants to USA shareholders, it was late a week and some sold them early prior other shareholders had warrants in their accounts.
They got the patent today, but look at the stock… no liquidity, no interest to buy.
Why?
Because to many promises he has made and never delivered anything that shareholders could benefit.
The stock should have been .30 to .50 today with this news. Look at it where it is.
Moreau need miracles or extra ordinary news development to get back shareholders trust him again. Having YouTube videos as PR are not helping him.
We know who has benefiting from his actions, not shareholders.
The best thing for Algernon will be Moreau resigns and they can replace him with someone who knows what he is doing not just talk and promises.
Having Patent give them leverage for hopefully Money jump- in verse Last Shares Sold was for .20 CAD or .15 AGNPF with .25 CAD Warrants
And there’s not enough Cash-On-Hand to finish the Quarter and need another $200,000 to finish Quarter - JMO
1,000,000 x $0.20 is $200,000
What happens going forward after patent granted … anyone?
Grant of U.S. Patent for Repirinast in NAFLD and NASH[/b[
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Grant-of-US-Patent-for-Repirinast-in-NAFLD-and-NASH?id=413131
Myself as well..
the microdosing for stroke is very exciting
Yes! smoki... That is the strong Ifenprodil research data that apparently AGN is now trying to sell (or still to gather a sponsor?) instead of running the 180 patient CT itself.
Thanks for reposting this news so we can all see the strong results and P values AGN saw during that 2a CT, as a "Secondary" side set of data that was originally for COVID/Long COVID.
It would be too expensive to do both the DMT Microdose for Stroke and this follow on for Ifenprodil CC/IPF. I agree with the DMT path and selling the "rights " for the CC/IPF Ifenprodil research to move that one forward, asap,...JMHO...
...GLTA...
Phase 2
40 patients
Find a stroke -not for profit - to help fund
Biometric of neuronal cell growth
and patient improvement ..
Means the pathway is multi billions..
Chris just tell us how you will reward
Agnpf shareholders with success.
Thx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |